Trial intelligence / Profile preview

Capecitabine added to carboplatin-based neoadjuvant chemotherapy for early triple-negative breast cancer

2018-002080-25Phase 3Active

Sponsor: Skåne University Hospital
Start: Mar 2019
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of capecitabine and carboplatin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Skåne University Hospital. Primary endpoint: Pathologic complete response. Started Mar 2019; status: active.

Drugs

capecitabinecarboplatin

Conditions

triple-negative breast cancer (TNBC)

Beyond the preview

Go deeper on 2018-002080-25.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2018-002080-25.